Statement of Changes in Beneficial Ownership (4)
February 15 2020 - 1:04AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Manzo Louis |
2. Issuer Name and Ticker or Trading Symbol
CAPRICOR THERAPEUTICS, INC.
[
CAPR
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR |
3. Date of Earliest Transaction
(MM/DD/YYYY)
2/12/2020 |
(Street)
BEVERLY HILLS, CA 90211
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (Right to Buy) | $1.39 | 2/12/2020 | | A | | 4500 | | (1) | 8/8/2029 | Common Stock | 4500 | (2) | 4500 | D | |
Stock Option (Right to Buy) | $1.39 | 2/12/2020 | | A | | 2550 | | (3) | 1/2/2028 | Common Stock | 2550 | (2) | 2550 | D | |
Stock Option (Right to Buy) | $1.39 | 2/12/2020 | | A | | 2356 | | (4) | 1/3/2027 | Common Stock | 2356 | (2) | 2356 | D | |
Stock Option (Right to Buy) | $1.39 | 2/12/2020 | | A | | 3000 | | (5) | 6/2/2026 | Common Stock | 3000 | (2) | 3000 | D | |
Stock Option (Right to Buy) | $1.39 | 2/12/2020 | | A | | 1500 | | (5) | 3/3/2025 | Common Stock | 1500 | (2) | 1500 | D | |
Stock Option (Right to Buy) | $1.39 | 2/12/2020 | | A | | 1401 | | (5) | 3/6/2023 | Common Stock | 1401 | (2) | 1401 | D | |
Stock Option (Right to Buy) | $1.39 | 2/12/2020 | | A | | 27904 | | (5) | 4/27/2022 | Common Stock | 27904 | (2) | 27904 | D | |
Stock Option (Right to Buy) | $3.25 | 2/12/2020 | | D | | | 4500 | (1) | 8/8/2029 | Common Stock | 4500 | (2) | 0 | D | |
Stock Option (Right to Buy) | $15.70 | 2/12/2020 | | D | | | 2550 | (3) | 1/2/2028 | Common Stock | 2550 | (2) | 0 | D | |
Stock Option (Right to Buy) | $25.50 | 2/12/2020 | | D | | | 2356 | (4) | 1/3/2027 | Common Stock | 2356 | (2) | 0 | D | |
Stock Option (Right to Buy) | $31.20 | 2/12/2020 | | D | | | 3000 | (5) | 6/2/2026 | Common Stock | 3000 | (2) | 0 | D | |
Stock Option (Right to Buy) | $57.80 | 2/12/2020 | | D | | | 1500 | (5) | 3/3/2025 | Common Stock | 1500 | (2) | 0 | D | |
Stock Option (Right to Buy) | $3.70 | 2/12/2020 | | D | | | 1401 | (5) | 3/6/2023 | Common Stock | 1401 | (2) | 0 | D | |
Stock Option (Right to Buy) | $3.70 | 2/12/2020 | | D | | | 27904 | (5) | 4/27/2022 | Common Stock | 27904 | (2) | 0 | D | |
Explanation of Responses: |
(1) | 3,000 of the shares were vested on the date of grant. The remaining 1,500 shares will vest 1/48th on the first day of each month, commencing September 1, 2019, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. |
(2) | The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. |
(3) | 1,050 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2018, until the stock option becomes fully vested and exercisable. The remaining 1,500 shares will vest 1/12th on the first day of each month, commencing February 1, 2018, with the last month vesting on December 31, 2018. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. |
(4) | 856 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2017, until the stock option becomes fully vested and exercisable. The remaining 1,500 shares will vest 1/12th on the first day of each month, commencing February 1, 2017, with the last month vesting on December 31, 2017. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. |
(5) | The stock option award is fully vested and exercisable. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Manzo Louis C/O CAPRICOR THERAPEUTICS, INC. 8840 WILSHIRE BLVD., 2ND FLOOR BEVERLY HILLS, CA 90211 | X |
|
|
|
Signatures
|
/s/ Linda Marban, as Attorney-in-Fact | | 2/14/2020 |
**Signature of Reporting Person | Date |
Capricor Therapeutics (NASDAQ:CAPR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Capricor Therapeutics (NASDAQ:CAPR)
Historical Stock Chart
From Sep 2023 to Sep 2024